Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody

Rosanna Di Paola, Roberto Di Marco, Emanuela Mazzon, Tiziana Genovese, Klaus Bendtzen, Battesimo Macrì, Ferdinando Nicoletti, Salvatore Cuzzocrea

Research output: Contribution to journalArticlepeer-review

Abstract

CD30 ligand (CD30L) and its receptor CD30 are members of the tumor necrosis factor (TNF) and TNF receptor superfamilies that play a major role in inflammation and immune regulation. To gain insight into the in vivo role of CD30L/CD30 in inflammatory diseases, we have used carrageenan (CAR)-induced pleurisy in mice, a preclinical model of airway inflammation where type 1 proinflammatory cytokines such as interleukin (IL)-1 and TNF-α play a key pathogenic role. The data show that prophylactic treatment with anti-CD30L mAb markedly reduces both laboratory and histological signs of CAR-induced pleurisy. These data suggest involvement of CD30-mediated signals in acute immunoinflammatory pathways induced by CAR.

Original languageEnglish
Pages (from-to)64-73
Number of pages10
JournalClinical Immunology
Volume113
Issue number1
DOIs
Publication statusPublished - Oct 2004

Keywords

  • CD30L
  • Cytokine
  • Pleurisy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody'. Together they form a unique fingerprint.

Cite this